FUSILEV
LOE ApproachingNDAINTRAVENOUSSOLUTION
Approved
Mar 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FUSILEV is an intravenous solution approved in 2008 as a branded pharmaceutical product. The specific mechanism of action and therapeutic indication are not publicly available in this dataset, limiting assessment of its clinical role. It is marketed by Acrotech Biopharma as an NDA-approved drug.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting brand team focus is shifting toward defensive positioning and preparation for generic/biosimilar entry.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®
Started Apr 2013
0Non-Small Cell Lung Cancer
Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
Started Mar 2013
0Non Hodgkin's Lymphoma
Career Relevance
FUSILEV currently shows zero linked job openings, reflecting its LOE-approaching status and limited commercial expansion. Career roles on this product are primarily defensive and focused on market maintenance rather than growth.
Brand Manager
Worked on FUSILEV at Acrotech Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.